Treatment of Conditions Through Modulation of the Autonomic Nervous System During at Least One Predetermined Menstrual Cycle Phase

• US 20100119482A1
• Filed: 12/24/2009
• Published: 05/13/2010
• Est. Priority Date: 05/13/2004
• Status: Abandoned Application

• Current Assignee: Palo Alto Investors
• Original Assignee: Palo Alto Investors
• Inventors: Yun, Anthony Joonkyoo, Lee, Partic Yuarn-Bor
• Application Number:
  US12/647,247
• Publication Number:
  US 20100119482A1
• Time in Patent Office: Days
• US Class Current: 424/85.600
• CPC Class Codes: A61K 31/137 Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
• CPC Class Codes: A61K 31/4745 condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48
• CPC Class Codes: A61K 31/57 substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• CPC Class Codes: A61K 38/085 Angiotensins
• CPC Class Codes: A61K 38/095 Oxytocins; Vasopressins; Related peptides
• CPC Class Codes: A61K 38/2221 Relaxins
• CPC Class Codes: A61K 38/26 Glucagons
• CPC Class Codes: A61K 38/4813 Exopeptidases (3.4.11. to 3.4.19)
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 15/18 Feminine contraceptives
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 5/24 of the sex hormones
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system

Abstract

Methods are provided for treating a subject for a condition. In accordance with the subject methods, at least a portion of a subject'"'"'s autonomic nervous system is modulated during at least one predetermined phase of the subject'"'"'s menstrual cycle to alter the parasympathetic activity/sympathetic activity ratio in a manner that is effective to treat the subject for the condition. The subject methods find use in the treatment of a variety of different conditions, including various disease conditions, that increase in severity and/or occurrence during one or more phases of the menstrual cycle. Also provided are systems and kits for use in practicing the subject methods.

Claims

1-68. -68. (canceled)

69. A multi-dose pharmacological agent package comprising:

a plurality of unit dosage forms of a pharmacological agent in a single pack, wherein the plurality of unit dosage forms is selected to modulate at least a portion of the autonomic nervous system to increase the parasympathetic activity/sympathetic activity ratio in a manner effective to treat a female subject for a condition which is increased in severity or occurrence during a phase of the subject'"'"'s menstrual cycle.

70. The multi-dose package according to claim 69, wherein the plurality of unit dosage forms comprises unit dosage forms for daily administration.

71. The multi-dose package according to claim 69, wherein the plurality of unit dosage forms is in the form of a monthly pack.

72. The multi-dose package according to claim 69, wherein the plurality of unit dosage forms is sufficient to treat the subject for 30 to 90 days.

73. The multi-dose package according to claim 69, wherein the plurality of unit dosage forms comprises two different dosages of the pharmacological agent.

74. The multi-dose package according to claim 73, wherein the number of unit dosage forms of a first dosage in the pack is equal to the number of days of a particular phase of the subject'"'"'s menstrual cycle over the treatment period.

75. The multi-dose package according to claim 69, wherein the pack further comprises a second pharmacological agent.

76. The multi-dose package according to claim 75, wherein the second pharmacological agent is effective for treating the subject for a second condition which is increased in severity or occurrence during a phase of the subject'"'"'s menstrual cycle.

77. The multi-dose package according to claim 69, wherein each of the unit dosage forms is individually packaged.

78. A method of treating a female subject for a condition which is increased in severity or occurrence during a phase of the subject'"'"'s menstrual cycle, the method comprising:

administering to the subject one of a plurality of unit dosage forms of a pharmacological agent contained in a single pack, wherein the plurality of unit dosage forms is selected to modulate at least a portion of the autonomic nervous system to increase the parasympathetic activity/sympathetic activity ratio in a manner effective to treat the subject for a condition which is increased in severity or occurrence during a phase of the subject'"'"'s menstrual cycle.

79. The method according to claim 78, wherein the plurality of unit dosage forms comprises unit dosage forms for daily administration.

80. The method according to claim 78, wherein the plurality of unit dosage forms is in the form of a monthly pack.

81. The method according to claim 78, wherein the plurality of unit dosage forms is sufficient to treat the subject for 30 to 90 days.

82. The method according to claim 78, wherein the plurality of daily unit dosage forms comprises two different dosages of the pharmacological agent.

83. The method according to claim 82, wherein the number of daily unit dosage forms of a first dosage in the pack is equal to the number of days of a particular phase of the subject'"'"'s menstrual cycle.

84. The method according to claim 78, wherein the pack further comprises a second pharmacological agent.

85. The method according to claim 84, wherein the second pharmacological agent is effective for treating the subject for a second condition which is increased in severity or occurrence during a phase of the subject'"'"'s menstrual cycle.

86. The multi-dose package according to claim 78, wherein each of the unit dosage forms is individually packaged.